Omakase Lab – P&R Orphan Drugs (2012-2016)

//Omakase Lab – P&R Orphan Drugs (2012-2016)

Omakase Lab – P&R Orphan Drugs (2012-2016)

In this report we identify the P&R situation in Spain of ODs approved by the European Commission between 2012-2016, and we analyse potential favourable ODs profiles for P&R approval in Spain, based on clinical, economic and institutional reimbursement variables.

Download file

2020-09-25T13:53:30+00:00September 19th, 2018|Omakase thought leadership Lab|

Leave A Comment